|
09 Sep 2025 |
Cipla
|
Consensus Share Price Target
|
1541.20 |
1676.69 |
- |
8.79 |
buy
|
|
|
|
|
13 May 2023
|
Cipla
|
BOB Capital Markets Ltd.
|
1541.20
|
1170.00
|
937.45
(64.40%)
|
Target met |
Buy
|
|
|
Q4 EBITDA/PAT grew 57%/45% YoY but missed consensus by 5%/30% on higher R&D spend, field force expansion and other costs
|
|
01 Mar 2023
|
Cipla
|
Prabhudas Lilladhar
|
1541.20
|
1070.00
|
899.60
(71.32%)
|
Target met |
Buy
|
|
|
|
|
28 Feb 2023
|
Cipla
|
Motilal Oswal
|
1541.20
|
990.00
|
906.40
(70.04%)
|
Target met |
Neutral
|
|
|
|
|
27 Jan 2023
|
Cipla
|
Bonanza
|
1541.20
|
|
1047.25
(47.17%)
|
|
Strategy Note
|
|
|
Since the last result, the prices have corrected till Q1: 22-23 result range and Pivot level of 1,040. Till Cipla sustains above these levels chance of bouncing back is very high. One can start buying in Cipla above 20EMA that is 1,078.
|
|
27 Jan 2023
|
Cipla
|
ICICI Securities Limited
|
1541.20
|
1082.00
|
1035.25
(48.87%)
|
Target met |
Hold
|
|
|
Cipla’s Q3FY23 performance was largely in line with our estimates. Revenue grew 6% YoY to Rs58.1bn (I-Sec: Rs.58.8bn) driven by a strong uptick in US revenue (US$195mn, +8.9% QoQ), which partially benefitted from continued traction in Revlimid and a strong seasonal quarter of its key products.
|
|
27 Jan 2023
|
Cipla
|
Axis Direct
|
1541.20
|
1300.00
|
1047.25
(47.17%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a TP of Rs 1,300/share.
|
|
27 Jan 2023
|
Cipla
|
SMC online
|
1541.20
|
|
1047.25
(47.17%)
|
|
Results Update
|
|
|
|
|
27 Jan 2023
|
Cipla
|
ICICI Direct
|
1541.20
|
1290.00
|
1047.25
(47.17%)
|
Target met |
Buy
|
|
|
|
|
26 Jan 2023
|
Cipla
|
BOB Capital Markets Ltd.
|
1541.20
|
1250.00
|
1035.25
(48.87%)
|
Target met |
Buy
|
|
|
Q3 revenue grew 6% YoY to Rs 58bn (11% ex-Covid sales last year) driven by US business and despite a sharp decline in SAGA
|
|
15 Dec 2022
|
Cipla
|
Motilal Oswal
|
1541.20
|
1180.00
|
1089.40
(41.47%)
|
Target met |
Neutral
|
|
|
|